JP2008546833A5 - - Google Patents

Download PDF

Info

Publication number
JP2008546833A5
JP2008546833A5 JP2008519017A JP2008519017A JP2008546833A5 JP 2008546833 A5 JP2008546833 A5 JP 2008546833A5 JP 2008519017 A JP2008519017 A JP 2008519017A JP 2008519017 A JP2008519017 A JP 2008519017A JP 2008546833 A5 JP2008546833 A5 JP 2008546833A5
Authority
JP
Japan
Prior art keywords
muc
based formulation
weeks
subject
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008519017A
Other languages
English (en)
Japanese (ja)
Other versions
JP5364371B2 (ja
JP2008546833A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2006/002771 external-priority patent/WO2007015171A2/en
Publication of JP2008546833A publication Critical patent/JP2008546833A/ja
Publication of JP2008546833A5 publication Critical patent/JP2008546833A5/ja
Application granted granted Critical
Publication of JP5364371B2 publication Critical patent/JP5364371B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008519017A 2005-06-28 2006-06-27 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法 Expired - Fee Related JP5364371B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69423305P 2005-06-28 2005-06-28
US60/694,233 2005-06-28
PCT/IB2006/002771 WO2007015171A2 (en) 2005-06-28 2006-06-27 Method of treating patients with a mucinous glycoprotein (muc-1) vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012215405A Division JP5858894B2 (ja) 2005-06-28 2012-09-28 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法

Publications (3)

Publication Number Publication Date
JP2008546833A JP2008546833A (ja) 2008-12-25
JP2008546833A5 true JP2008546833A5 (enExample) 2009-08-13
JP5364371B2 JP5364371B2 (ja) 2013-12-11

Family

ID=37708986

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008519017A Expired - Fee Related JP5364371B2 (ja) 2005-06-28 2006-06-27 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法
JP2012215405A Expired - Fee Related JP5858894B2 (ja) 2005-06-28 2012-09-28 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法
JP2015186321A Pending JP2016014046A (ja) 2005-06-28 2015-09-24 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012215405A Expired - Fee Related JP5858894B2 (ja) 2005-06-28 2012-09-28 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法
JP2015186321A Pending JP2016014046A (ja) 2005-06-28 2015-09-24 ムチン糖タンパク質（ｍｕｃ−１）ワクチンによって患者を処置する方法

Country Status (16)

Country Link
US (3) US8871250B2 (enExample)
EP (2) EP1896051B1 (enExample)
JP (3) JP5364371B2 (enExample)
CN (2) CN101309697A (enExample)
AR (1) AR054526A1 (enExample)
AU (1) AU2006274651B2 (enExample)
BR (1) BRPI0613510A2 (enExample)
CA (1) CA2613327A1 (enExample)
DK (2) DK1896051T3 (enExample)
ES (2) ES2526344T3 (enExample)
HK (1) HK1219417A1 (enExample)
HU (1) HUE026490T2 (enExample)
PL (2) PL2366400T3 (enExample)
PT (2) PT2366400E (enExample)
TW (2) TW201615208A (enExample)
WO (1) WO2007015171A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198400B2 (en) 2001-03-27 2012-06-12 Oncothyreon, Inc. Vaccine for modulating between T1 and T2 immune responses
US20060069238A1 (en) * 2002-04-15 2006-03-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
TWI395591B (zh) * 2004-04-01 2013-05-11 Oncothyreon Inc 黏液性糖蛋白（ｍｕｃ-１）疫苗
ES2526344T3 (es) * 2005-06-28 2015-01-09 Oncothyreon Inc. Método para el tratamiento de pacientes con una vacuna de glicoproteína mucinosa (MUC-1)
BRPI0923001A2 (pt) * 2008-12-17 2018-09-18 Oncothyreon Inc método de produção de lipossomas pequenos
DK2411815T3 (en) * 2009-03-24 2015-11-30 Transgene Sa Biomarker MONITORING OF PATIENTS
DK2419728T3 (da) * 2009-04-17 2014-02-03 Transgene Sa Biomarkør til at overvåge patienter
GB0910751D0 (en) * 2009-06-23 2009-08-05 Procure Therapeutics Ltd Prostate cancer vaccine
RU2552292C2 (ru) 2009-07-10 2015-06-10 Трансжене Са Биомаркер для отбора пациентов и связанные с ним способы
WO2011133429A1 (en) 2010-04-19 2011-10-27 Ezose Sciences, Inc Cancer-related glycopeptide epitopes, antibodies and methods of use
KR20140023903A (ko) 2011-02-24 2014-02-27 온코타이레온, 인코포레이티드 항원보강제를 갖는 muc1 기초 당지질펩티드 백신
SG11201509357WA (en) * 2013-05-14 2015-12-30 Merck Patent Gmbh Method of treating lung cancer by vaccination with muc-1 lipopeptide
RU2016109938A (ru) * 2013-08-21 2017-09-26 Куревак Аг Композиция и вакцина для лечения рака предстательной железы
US9467478B1 (en) 2013-12-18 2016-10-11 vIPtela Inc. Overlay management protocol for secure routing based on an overlay network
WO2015099224A1 (ko) 2013-12-26 2015-07-02 주식회사 포스코 압연장치, 연주압연장치 및 방법
US11433143B2 (en) * 2017-05-18 2022-09-06 The Regents Of The University Of California Nano-enabled immunotherapy in cancer
CN112190688A (zh) * 2020-09-09 2021-01-08 广州医科大学附属第一医院（广州呼吸中心） 粘蛋白muc1在制备具有延缓肺衰老功效的药物中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
EP0203676B1 (en) 1985-04-19 1992-01-29 The Wistar Institute Of Anatomy And Biology Vaccine for generating an immunogenic t cell response protective against a virus
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5993823A (en) 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
US5580563A (en) 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
WO1995027505A1 (en) 1994-04-12 1995-10-19 Biomira, Inc. Cellular immune response-specific antigens and uses therefor
CA2189356A1 (en) 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
AU6260796A (en) 1995-06-07 1996-12-30 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecul es and uses thereof
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP2001510440A (ja) 1996-03-20 2001-07-31 スローン―ケタリング・インスティテュート・フォー・キャンサー・リサーチ ムチン接合体ペプチドワクチン
CA2252055C (en) 1996-04-11 2007-01-16 The University Of British Columbia Fusogenic liposomes
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
WO1998050527A1 (en) * 1997-05-08 1998-11-12 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2776926B1 (fr) 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US20020051813A1 (en) * 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
JP2003519096A (ja) 1999-08-18 2003-06-17 アルタレックス コーポレーション Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法
US7147850B2 (en) * 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
JP2003510094A (ja) * 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
WO2001036433A2 (en) 1999-11-15 2001-05-25 Biomira, Inc. Synthetic lipid-a analogs and uses thereof
WO2001070265A2 (en) 2000-03-24 2001-09-27 Biomira, Inc. Lipopeptide adjuvants
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
EP1343476B1 (en) 2000-12-01 2008-05-28 Biomira Inc. Preparation of large liposomes by infusion into peg
US8198400B2 (en) 2001-03-27 2012-06-12 Oncothyreon, Inc. Vaccine for modulating between T1 and T2 immune responses
WO2003003985A2 (en) 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
US20060069238A1 (en) 2002-04-15 2006-03-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
ATE457733T1 (de) 2002-05-09 2010-03-15 Oncothyreon Inc Lipid-a- und andere kohlenhydrat-liganden-analoga
TWI395591B (zh) 2004-04-01 2013-05-11 Oncothyreon Inc 黏液性糖蛋白（ｍｕｃ-１）疫苗
ES2526344T3 (es) 2005-06-28 2015-01-09 Oncothyreon Inc. Método para el tratamiento de pacientes con una vacuna de glicoproteína mucinosa (MUC-1)

Similar Documents

Publication Publication Date Title
JP2008546833A5 (enExample)
RU2012149618A (ru) Менингококковые полипептиды fhbp
ES2318898T3 (es) Antigenos tumorales basados en el producto del gen wt1 supresor de tumor.
RU2009101387A (ru) Рекомбинантная вирусная вакцина
JP2006020648A5 (enExample)
JP2015505309A5 (enExample)
JP2007515393A5 (enExample)
JP2010529026A5 (enExample)
JP2012500001A5 (enExample)
KR20130024888A (ko) 폴리펩티드
JP2008530245A5 (enExample)
DE60239937D1 (de) Hilfszusammensetzung für vakzinen, die über die schleimhaut oder durch injektion verabreicht werden
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
JP2005537800A5 (enExample)
JP2004535187A (ja) アジュバントとしてのコレラホロトキシンの突然変異形
RU2007139915A (ru) Haemophilus influenzae типа в
JP2008539187A5 (enExample)
JP2008543847A5 (enExample)
JP2014506562A5 (ja) 治療的免疫応答及び予防的免疫応答の両方を誘発するポリペプチド（複数可）保持ＣｙａＡ及びその使用
CN101754768B (zh) 用作癌症疫苗的存活蛋白肽
RU2015100889A (ru) Вакцины для менингококка серогруппы х
Bubenik et al. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.
Gonzalez et al. Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment
CA2492938A1 (en) Cancer vaccines containing epitopes of oncofetal antigen
WO2005025494A3 (en) Vaccine immunotherapy for immune suppressed patients